Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
by PR Newswire
Oct 08, 2024 4:38 am
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
ContinueOR
See our subscription options.
Already have an account? Log in here